12/22/2014 | PP | Vanda Pharmaceuticals to conduct registered direct offering of shares
|
11/3/2014 | PP | Vanda greenshoe exercised in $66.7 million public offering of stock
|
10/29/2014 | PP | Vanda Pharmaceuticals prices $58 million public offering of stock
|
10/28/2014 | PP | Vanda Pharmaceuticals reports plans to price public offering of stock
|
8/7/2013 | PP | Vanda prices $52.14 million public sale of stock at $11.14 per share
|
8/6/2013 | PP | Vanda Pharmaceuticals intends to price public sale of common shares
|
1/31/2011 | CVPF | Vanda files $50 million shelf for stock, debt and preferreds
|
2/23/2009 | SS | Vanda Pharmaceuticals opposed to shareholder's proposals, proxy battle
|
11/18/2008 | SS | Market Commentary: Atmel buyers back out; phone deals start approval path; Tang not alone in loss of Lehman-held shares
|
11/17/2008 | SS | Tang Capital begins rebuilding stake in Vanda after Lehman bankruptcy
|
11/2/2007 | CV | Vanda pulls $100 million convertibles offering
|
11/2/2007 | CV | Market Commentary: Synaptics, Cray, Millennium up on earnings; Itron gutted; new issues open flat; Vanda doesn't open at all
|
11/1/2007 | CV | Market Commentary: Successful test spurs United Therapeutics; iStar, Countrywide down with financials; tough day for four new issues
|
10/31/2007 | CV | Market Commentary: Equinix surges on earnings; Newmont shines; Chemed scares investors; debt strangles CommScope
|
10/31/2007 | CV | Vanda launches $100 million convertibles due 2014 at 3.875%-4.375% coupon, up 17.5%-22.5%
|
11/2/2006 | BT | Vanda doubles R&D spending in third-quarter 2006
|
10/24/2006 | BT | Market Commentary: United Therapeutics climbs 9%; Vanda gains to another new high; Titan flat; Critical retreats by 8%
|
8/30/2006 | BT | Vanda completes schizophrenia, insomnia phase 3 trials ahead of schedule
|
8/3/2006 | BT | Market Commentary: Titan zooms; Vanda slides; LAB goes public in Canada; Indevus up, NitroMed dives
|
6/23/2006 | BT | Vanda: data from phase 2 trial shows effectiveness of VEC-162 in treatment of insomnia
|
6/13/2006 | BT | Vanda to release phase 2 data for sleep disorder compound at professional society meeting
|
5/18/2006 | BT | Vanda ahead of schedule in iloperidone trial, outside factors could prevent early results
|
4/21/2006 | BT | Vanda greenshoe exercised, raising IPO to $59.64 million
|
4/17/2006 | BT | Market Commentary: Invitrogen falls on lower sales forecast; Alkermes rises, dips; Targacept, Vanda gain; Dyax off
|
4/12/2006 | BT | Market Commentary: Vanda, Targacept tank on debut; Omrix IPO in limbo; Novavax, KOS climb; Discovery soars after hours
|
4/12/2006 | BT | New Issue: Vanda Pharma prices $57.5 million IPO at $10 per share, below range of $12 to $14
|
12/30/2005 | BT | Vanda Pharmaceuticals files for $75 million IPO of stock
|
12/12/2005 | BT | Vanda begins phase 3 trial of antipsychotic agent iloperidone licensed from Titan
|